International market profiling and prioritisation analysis for a new therapy for a rare neurological disorder ​

• The client had developed a therapy for a rare neurological disorder and was aware of structural barriers for access/patient uptake across 16 global markets (covering APAC, MENA, and LATAM) ​
• The company required a detailed assessment of the structural barriers/opportunities to optimise the clinical and commercial opportunity for the asset​
• This was required to inform prioritisation of activities to drive growth across selected markets (and go/no-go decision making for country launch viability)​

‍

• Detailed analysis of the current treatment landscape for target patients across 16 global markets (including the key drivers of decision making)​
• Analysis of the policy/economic/logistical barriers for access to treatments for target patients and the requirements/feasibility to address these to support optimal access and uptake of treatment ​
• Development of recommendations on feasible opportunities/priority activities to drive access/growth of treatment for target patients ​

‍

• A desk research programme was completed across the 16 scope markets to inform the current treatment landscape and policy framework for target patients​
• Primary research across 16 markets validated the treatment landscape, barriers/ opportunities for driving access/uptake to treatment and predicted impact on prescribing ​
• Findings were synthesised into a scoring framework across markets, to inform prioritisation of launch/value demonstration activities across the APAC, MENA and LATAM regions ​

• The client received a detailed assessment of the current clinical/access landscape for target patients across 16 global markets and the practical requirements to optimise the clinical/commercial opportunity for the new therapy ​
• This provided the client team with an actionable, coherent framework to inform prioritisation of launch/value demonstration activities across the APAC, MENA and LATAM regions ​

‍